Peter Hecht, PhD
Chief Executive Officer
Our Team
We are led by an accomplished team with an exceptional track record of discovering, developing, and commercializing meaningful therapies for patients while creating value for stockholders. Our founding team has deep knowledge and significant experience in cGMP pathway research and development.
Our Chief Executive Officer, Peter Hecht, PhD, served as the co-founder and chief executive officer of Ironwood Pharmaceuticals from 1998 to 2019. Under his leadership, Ironwood grew from nine Ph.D. scientists to a commercial biotechnology company that discovered, developed and is now commercializing LINZESS® – the branded prescription market leader in its class. Additionally, during his tenure the company pioneered new areas of science, delivered a promising development portfolio with multiple innovative drug candidates and established a valuable network of global partnerships. Through a combination of private and public equity, structured debt and partnerships, Peter and his team raised over one billion dollars to fund these efforts. He also served on the Ironwood board from 1998 to 2019, and currently serves on the board of Kallyope Inc., a privately held biotechnology company. Prior to founding Ironwood, Peter was a research fellow at Whitehead Institute for Biomedical Research. Peter earned a B.S. in mathematics and an M.S. in biology from Stanford University, and a Ph.D. in molecular biology from the University of California at Berkeley.
Our Chief Operating Officer, Cheryl Gault, has nearly 20 years of biopharma industry experience. Cheryl is currently responsible for corporate and business development, program management, portfolio strategy, new product planning, and corporate strategy functions. Her experience includes marketing, sales, new product planning, launch and commercial strategy in various therapeutic areas including gastroenterology, rheumatology, and orthopedics. Cheryl played a central role while at Ironwood in the successful launch of LINZESS®, the $1B market leader in IBS. Prior to that, Cheryl was at Genzyme Corporation in a variety of sales and marketing roles in the biosurgery division, including a leadership role in the launch of Synvisc-ONE, an injectable for the treatment of osteoarthritis. Cheryl brings a unique commercial perspective to our drug development team.
Our Chief Financial Officer, Anjeza Gjino, played a pivotal role in executing the Cyclerion spin-off and in building the company’s systems and management processes. Anjeza oversees the finance, IT, and human resources teams and activities, including strategic funding and capital allocation efforts. Anjeza also serves as Corporate Secretary. Prior to joining Cyclerion, Anjeza served as head of Financial Planning and Analysis at Ironwood Pharmaceuticals where she built the financial infrastructure to help the company launch its first product, LINZESS®, and to transition from a research organization to a commercial one. Previously, Anjeza held various finance roles at PerkinElmer leading and supporting capital allocation and business transformation initiatives. During her 13 years at Ironwood and PerkinElmer, Anjeza provided financial advice and business partnering to all functions across the organization, including strategic planning, portfolio optimization, business development valuations and commercial execution. Anjeza holds an M.B.A from the Massachusetts Institute of Technology and a B.S in Corporate Finance from Bentley University.
Our Senior Vice President of External Innovation, Todd Milne, PhD, brings more than 20 years of experience in the biopharma industry. Prior to Cyclerion, Todd was a co-founder of Ironwood Pharmaceuticals where he held a number of scientific program and functional leadership roles, including leading sGC stimulator discovery and early development efforts at Ironwood. He is also one of the inventors of LINZESS®, a market-leading treatment for irritable bowel syndrome with constipation and chronic idiopathic constipation. Prior to founding Ironwood, Todd was a postdoctoral research fellow at Whitehead Institute for Biomedical Research. Todd earned a B.S. in molecular biophysics and biochemistry from Yale University and a Ph.D. in microbiology and molecular genetics from Harvard University.
Our Vice President of Clinical Strategy, Jennifer Chickering, PhD, has over 20 years of experience in biotech, holding diverse roles spanning multiple therapeutic areas including CNS, cardiovascular/cardiometabolic, GI, and rare diseases. Jennifer leads teams across development, building clinical plans with a focus on innovative early designs to support successful later-stage development. Additionally, she oversees medical writing and works with business development on in- and out-licensing efforts. Prior to Cyclerion, Jennifer held roles at Ironwood Pharmaceuticals across Medical Writing and Clinical Research. Before that, Jennifer worked with multiple biotechs authoring regulatory documents, white papers, and grant applications, including a Grand Challenges in Global Health Proposal for the Bill and Melinda Gates Foundation ($2.7M awarded). Jennifer earned a BS in Biology from Rhodes College and a PhD in Ecology and Evolutionary Biology from Brown University.
Our Vice President of Pharmaceutical Development, Bill Kissel, PhD, brings more than 20 years of pharmaceutical development experience in the biopharma industry. As the leader of Pharmaceutical Development, Bill is responsible for Analytical Development, Chemical Development, Formulation Development, and Clinical Supplies. Prior to Cyclerion, Bill held several leadership positions in Pharmaceutical Development and Technical Operations at Ironwood Pharmaceuticals and played a key role in bringing LINZESS® to market. Prior to Ironwood, Bill was in Chemical Development at Pfizer and Parke-Davis where he played an important role in the LYRICA® approval. Bill earned a BS in Chemistry from University of Illinois and a PhD in Chemistry from Indiana University and was a postdoctoral research fellow at Emory University.
Our Scientific Advisors
The women and men on our advisory boards bring diverse, global perspectives from basic science, clinical practice and industry to help us create better medicines for CNS disorders.
Claudio Babiloni, PhD
Associate Professor of Physiology & Head of the Laboratory of Neurosciences of Human Higher Functions, Department of Physiology and Pharmacology “V. Erspamer” at Sapienza University of Rome, Immediate Past Chair of the Alzheimer’s Association’s International Society to Advance Alzheimer’s Research and Treatment (ISTAART) Electrophysiology Professional Interest Area, and Senior Co-Chair of the Special Interest Group on Advanced EEG/MEG Techniques in Clinical Neurophysiology at the International Federation of Clinical Neurophysiology (IFCN)
Andrew E. Budson, MD
Chief of Cognitive & Behavioral Neurology and Director of the Center for Translational Cognitive Neuroscience at the Veterans Affairs Boston Healthcare System, Associate Director and Education Leader of the Boston University Alzheimer’s Disease Research Center, Professor of Neurology at Boston University School of Medicine, and Lecturer in Neurology at Harvard Medical School
Mark Currie, PhD
Chair of Scientific Advisory Board at Cyclerion Therapeutics; Director at Ironwood Pharmaceuticals; and Director at Science Exchange
Marni J. Falk, MD
Executive Director, Mitochondrial Medicine Frontier Program, The Children’s Hospital of Philadelphia and Professor, Division of Human Genetics, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania.
Michael Heneka, MD, PhD
Unit Leader of Neuroinflammation at the German Center for Neurodegenerative Disease, Professor of Neurodegenerative Disease and Geronto-Psychiatry-Neurology at the University of Bonn, and Adjunct Professor, Department of Infectious Diseases and Immunology at the University of Massachusetts Medical School
Robert C. Malenka, MD, PhD
Pritzker Professor of Psychiatry and Behavioral Sciences, Director of the Nancy Pritzker Laboratory, and Deputy Director of the Wu Tsai Neurosciences Institute at Stanford University
David H. Salat, PhD
Director, Brain Aging and Dementia (BAnD) Laboratory, Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital; Associate Professor in Radiology at Harvard Medical School; and Director, Neuroimaging Research for Veterans (NeRVe) Center, Veterans Affairs (VA) Boston Healthcare System.
Daniela Salvemini, PhD
Professor of Pharmacology and Physiology and Director of the Henry and Amelia Nasrallah Center for Neuroscience at St. Louis University
Harald H.H.W. Schmidt, MD, PhD, PharmD
Professor of Pharmacology and Chairman of the Department of Pharmacology and Personalized Medicine at Maastricht University
Eric Smith, MD
Professor of Neurology and the Katthy Taylor Chair in Vascular Dementia at the University of Calgary, Calgary Stroke Program
M Brandon Westover, MD, PhD
Physician Investigator in Neurology at Mass General Research Institute, Associate Professor of Neurology at Harvard Medical School, Associate Neurologist in Neurology at Massachusetts General Hospital, and Co-Founder, Beacon Biosignals
Chris Wright, MD, PhD
Chief Medical Officer at AavantiBio, Advisory Board Member at Clora, Inc., and Affiliate Member, Department of Pharmacology & Therapeutics at McGill University
